Abstract
The proprotein convertases (PCs) are serine proteases involved in various physiological processes and their overactivity or inactivity has been linked to different disorders. PCs are responsible for the proteolytic processing of various polypeptide precursors. Here, we discuss the effect of their N-terminal prosegments on various PC substrates processing and functions.
Keywords: Proprotein convertases, prosegments, inhibitors, processing, maturation, substrates
Medicinal Chemistry
Title: Inhibitory Feature of the Proprotein Convertases Prosegments
Volume: 4 Issue: 2
Author(s): Abdel-Majid Khatib, Yannick Bontemps, Marion Lapierre, Geraldine Siegfried and Fabien Calvo
Affiliation:
Keywords: Proprotein convertases, prosegments, inhibitors, processing, maturation, substrates
Abstract: The proprotein convertases (PCs) are serine proteases involved in various physiological processes and their overactivity or inactivity has been linked to different disorders. PCs are responsible for the proteolytic processing of various polypeptide precursors. Here, we discuss the effect of their N-terminal prosegments on various PC substrates processing and functions.
Export Options
About this article
Cite this article as:
Khatib Abdel-Majid, Bontemps Yannick, Lapierre Marion, Siegfried Geraldine and Calvo Fabien, Inhibitory Feature of the Proprotein Convertases Prosegments, Medicinal Chemistry 2008; 4 (2) . https://dx.doi.org/10.2174/157340608783789176
DOI https://dx.doi.org/10.2174/157340608783789176 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Role of ROS and RNS in Regulating Life and Death of Blood Monocytes
Current Pharmaceutical Design Adjunctive Therapies in Severe Pneumonia in Critical Care Patients
Infectious Disorders - Drug Targets Common Therapeutic Modalities Against Diabetes and Associated Cardiovascular Disease
Current Vascular Pharmacology Neuroprotective Effects of Drug-Induced Therapeutic Hypothermia in Central Nervous System Diseases
Current Drug Targets Yin and Yang of Polyphenols in Cancer Prevention: A Short Review
Anti-Cancer Agents in Medicinal Chemistry Exercise for the Overweight and Obese
Current Pharmaceutical Design Editorial (Thematic Issue: Cardio-Metabolic Complications: Current Perspective and Future Developments)
Current Pharmaceutical Design The Relationship Between Inflammation, Dyslipidemia and Physical Exercise: From the Epidemiological to Molecular Approach
Current Diabetes Reviews Renal Phosphate Handling in Antiretroviral-naive HIV-Infected Patients
Infectious Disorders - Drug Targets Cannabinoid Hyperemesis Syndrome
Current Drug Abuse Reviews The Relationship between Diet and Frailty in Aging
Endocrine, Metabolic & Immune Disorders - Drug Targets From Brain Ischemia-Reperfusion Injury to Possible Sporadic Alzheimers Disease
Current Neurovascular Research Peroxisome Proliferator-Activated Receptor (PPAR) Agonists as Promising New Medications for Drug Addiction: Preclinical Evidence
Current Drug Targets Update on Statins: Hope for Osteoporotic Fracture Healing Treatment
Current Drug Targets Role of the Hypoxic Microenvironment in the Antitumor Activity of Tyrosine Kinase Inhibitors
Current Medicinal Chemistry Designing Proteins That Work Using Recombinant Technologies
Current Pharmaceutical Biotechnology Editorial (Thematic Issue: Frontiers in Atherosclerosis, Heart Disease and Diabetes)
Cardiovascular & Hematological Disorders-Drug Targets Garlic for Cardiovascular Disease: Prevention or Treatment?
Current Pharmaceutical Design Probiotics and Oral Health
Current Pharmaceutical Design Effects of Fenofibrate on the Expression of Small Heterodimer Partner (SHP) and Cytochrome P450 (CYP) 2D6
Drug Metabolism Letters